An antibody engineered to prevent excessive bleeding in patients with severe hemophilia A may be safe and effective, and require fewer injections than existing options, according to a first-in-human study of the treatment.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1ODuRLt
No comments:
Post a Comment